This analysis not only confirmed the overall significant downregulation of ROMO1 in RA and T1D patients but also precisely located this expression change primarily in CD4 + T cells, CD14 + HLA-DR + monocytes, and other immune cells. This evidence concerns the gene CD4 and type 1 diabetes mellitus.